Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe


Colagrossi L., Hermans L. E., Salpini R., Di Carlo D., Pas S. D., Alvarez M., ...Daha Fazla

BMC INFECTIOUS DISEASES, cilt.18, 2018 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1186/s12879-018-3161-2
  • Dergi Adı: BMC INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: HBV, HBsAg, Immune-escape, Stop-codons, Drug-resistance, CHRONIC HEPATITIS-B, SURFACE-ANTIGEN, VIRUS INFECTION, POSITIVE MOTHERS, GENE, REACTIVATION, PROTEIN, REPLICATION, PROPHYLAXIS, VACCINATION
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Background: HBsAg immune escape mutations can favor HBV-transmission also in vaccinated individuals, promote immunosuppression-driven HBV-reactivation, and increase fitness of drug-resistant strains. Stop-codons can enhance HBV oncogenic-properties. Furthermore, as a consequence of the overlapping structure of HBV genome, some immune-escape mutations or stop-codons in HBsAg can derive from drug-resistance mutations in RT. This study is aimed at gaining insight in prevalence and characteristics of immune-associated escape mutations, and stop-codons in HBsAg in chronically HBV-infected patients experiencing nucleos(t)side analogues (NA) in Europe.